Tradestie Institutional Equity Comparison Engine

PACB vs MXCT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MXCT Overall Edge

MXCT Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MaxCyte, Inc. Common Stock (MXCT) driven by superior Growth & Margin, Options & Structure while PACB counters with relative strength in Momentum & Technical. Fundamentally, PACB trades at N/M Forward P/E with -333.0% operating margin (+5.5% YoY revenue) versus MXCT at N/M Forward P/E and -85.5% operating margin (+48.7% YoY). In options structure, PACB sits in BREAKDOWN (97th %ile IV; Dealer Gamma Walls on Pro) against MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
PACB N/M vs MXCT N/M Fwd P/E
Growth & Margin Winner MXCT
Op Margin -333.0% vs -85.5% ยท YoY +5.5% vs +48.7%
Momentum & Technical Winner PACB
1Y -7.4% vs -19.4% ยท 52W Pos 24% vs 63%
Options & Structure Winner MXCT
BREAKDOWN (97th %ile IV) vs UNCLASSIFIED (N/A IV)
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.63
-7.39% 1D
Market Cap $549.5M
1M Return -20.87%
1Y Return -7.39%
Forward P/E N/M
Unified AI Score
50.1 / 100 HOLD
Tech 40.0 Fund 55.0 Flow 70.0 Mom 60.0
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
1M Return -4.2%
1Y Return -19.41%
Forward P/E N/M
Unified AI Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PACB -7.39% MXCT -19.41% Spread: +12.02 pp (PACB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PACB Revenue MXCT Revenue PACB Op. Margin MXCT Op. Margin Margin Edge
FY2018 $80M N/A -128.4% N/A PACB
FY2019 $90M $10M -110.6% -93.7% MXCT
FY2020 $80M $20M -132.3% -71.6% MXCT
FY2021 $130M $20M -161.2% -84.3% MXCT
FY2022 $130M $30M -239.4% -95.2% MXCT
FY2023 $200M $20M -166.8% -247.7% PACB
FY2024 $150M $20M -308.0% -230.5% MXCT
FY2025 $160M $20M -346.2% -247.6% MXCT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PACB (2) vs MXCT (5)
Institutional Metric PACB MXCT Criterion Row Winner
Market Capitalization Scale $549.5M $132.2M Larger Scale PACB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +5.5% +48.7% Higher Growth MXCT
Operating Margin (TTM) Profitability -333.0% -85.5% Higher Margin MXCT
Net Profit Margin Profitability -81.3% -81.4% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -929.3% -16.9% Higher ROE MXCT
52-Week Range Position Momentum 24% ($1โ€“$3) 63% ($1โ€“$2) Stronger Trend MXCT
Beta / 30D Volatility Risk Regime 2.25ฮฒ ยท 104% Vol 1.19ฮฒ ยท 96% Vol Lower Realized Risk MXCT
Unified Institutional Score Composite Signal 50.1 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite PACB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PACB vs MXCT Buy Guide
PACB BREAKDOWN
16d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 97th %ile
IV Regime Extreme (>80th %ile)
Live PACB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MXCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PACB nor MXCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.